for the statements aimed at the Nordic European countries (other subjects, low quality, a small number, case studies), fifty papers remained. Thirty-two were review articles, including four systematic reviews, four guidelines/algorithms, one book, three definitions, and methodology articles, and eighteen clinical studies. The literature search results were evaluated independently by two reviewers who graded the clinical publications according to study type (A, B, or C) and assigned a level of evidence (level 1 to level 4) using the preestablished criteria.15 Of the eighteen clinical publications, most addressed cAEs impacting QoL, and only two studies (graded C-3 and B-2) evaluated a specific skincare regimen (Table 1).
Evidence and Opinion-Based Best Practice Recommendations
The reviewers drafted statements based on the selected literature before the meeting. During the virtual meeting, the NECOM group set and fine-tuned five consensus statements from the draft list of twelve statements and revised them online after the meeting. Through blinded reiterations and votes, the NECOM panel defined the final statements. The panel's consensus was established as an eighty percent agreement being obtained.
RESULTS
Statement 1: Dermatologic toxicities associated with cancer treatment are common and can significantly impact QoL and disrupt cancer treatment.
Depending on the anticancer treatment, various cAEs may occur.3,16,17 The NECOM group used the Common Terminology Criteria for Cutaneous Adverse Events (CTCAE) version 5.0.18 The CTCAE system has five grades (Grade 1: Mild, Grade 2: Moderate, minimal, local, or noninvasive intervention indicated, Grade 3: Severe, medically significant but not immediately life-threatening, Grade 4: Life-threatening consequences, urgent intervention indicated, Grade 5: Death related to the cAEs); however, not all five grades apply for cAEs.18 This paper focuses on best practice recommendations for oncology skincare programs. Therefore, only a short overview of cAEs is provided to inform clinicians on the conditions that may benefit from a skincare regimen.
Many studies are available on cAEs; however, information on prevention, treatment, and maintenance using general measures and OTC skincare is lacking.4-12
Depending on the anticancer treatment, various cAEs may occur.3,16,17 The NECOM group used the Common Terminology Criteria for Cutaneous Adverse Events (CTCAE) version 5.0.18 The CTCAE system has five grades (Grade 1: Mild, Grade 2: Moderate, minimal, local, or noninvasive intervention indicated, Grade 3: Severe, medically significant but not immediately life-threatening, Grade 4: Life-threatening consequences, urgent intervention indicated, Grade 5: Death related to the cAEs); however, not all five grades apply for cAEs.18 This paper focuses on best practice recommendations for oncology skincare programs. Therefore, only a short overview of cAEs is provided to inform clinicians on the conditions that may benefit from a skincare regimen.
Many studies are available on cAEs; however, information on prevention, treatment, and maintenance using general measures and OTC skincare is lacking.4-12
